Afinitor | MedDataX

Drug Profile

Afinitor is the brand name for everolimus, an mTOR-targeted medicine used in oncology and other indications. Everolimus is used as targeted therapy in renal cell cancer and other tumors, and it is also used as an immunosuppressant in transplant settings. The drug has multiple U.S. FDA approvals across indications.

Drug Class: mTOR inhibitor; antineoplastic and immunosuppressant agent
Approval Status: FDA approved (multiple indications, including US FDA approval for advanced kidney cancer in March 2009); prescription-only
Mechanism of Action: Binds FKBP12 and inhibits mTORC1 downstream signaling, impairing protein translation linked to cell cycle and glycolysis

Brand Names

Afinitor

Indications

\Advanced kidney cancer\
\Breast cancer (with exemestane)\
\Neuroendocrine tumors\
\Tuberous sclerosis complex-associated indications\

Related News

FDA Approves First-Line Acalabrutinib Regimen for CLL/SLL, Expands NSCLC Dosing Options

Feb 21, 2026

The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.

FDA Accepts Roche NDA for Giredestrant in ER+/HER2- Breast Cancer with ESR1 Mutations

Feb 20, 2026

The FDA has accepted Roche's new drug application for giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer, with a decision expected by December 18, 2026.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT01731158	Sequential Therapy in Metastatic Renal Cell Carinoma	COMPLETED	PHASE2